# Health Dividend

That was the [peace dividend](../../knowledge/economics/peace-dividend.llms.md): the money you get from buying 1% fewer explosions. Now here is the health dividend: what happens when you spend it on medicine instead.

Right now, somewhere in your regulatory system, a drug that already passed safety testing is sitting in a filing cabinet while the disease it treats keeps killing people. Somewhere else, a researcher with a promising compound for one of [6,650](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-diseases_without_effective_treatment) untreated diseases is filling out the same form for the fourth time. The health dividend is what happens when you stop doing this.

It is worth **[\$7.53 quadrillion (90% CI: \$3.08 quadrillion-\$12.8 quadrillion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_economic_value)**. That number is not a typo. I checked. Your economists checked. Everyone checked. It’s still that number. The rest of this chapter is the receipt.

## From Explosions to Trial Slots

[\$27.2 billion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_annual_funding) arrives from the [peace dividend](../../knowledge/economics/peace-dividend.llms.md). [Investor and political allocations](../../knowledge/solution/dih.llms.md) take their cut, leaving [\$21.8 billion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dih_treasury_to_medical_research_annual) for medical research ([80%](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dih_treasury_medical_research_pct) of the total). [Your decentralized FDA](../../knowledge/solution/dfda.llms.md)^([1](../references.llms.md#ref-dfda-spec-paper-2025),[2](../references.llms.md#ref-dfda-impact-paper-2025)) takes [\$40 million (90% CI: \$33.5 million-\$47.1 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_annual_opex) to keep the lights on. That leaves [\$21.7 billion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dih_treasury_trial_subsidies_annual) for trial subsidies.

I am now going to show you what that money buys. I apologize in advance for the number of numbers. Your species requires receipts before it will believe anything, even things that are obviously true. Especially things that are obviously true.

Your current system charges [\$41,000 (95% CI: \$20,000-\$120,000)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-traditional_phase3_cost_per_patient) per patient in a clinical trial. I asked why and was told “regulatory compliance, site management, and monitoring overhead,” which I believe is the human phrase for “permission costs more than medicine.” Pragmatic trials, the kind [your decentralized FDA](../../knowledge/solution/dfda.llms.md) runs, cost [\$929 (95% CI: \$97-\$3,000)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_pragmatic_trial_cost_per_patient). At that price, [\$21.7 billion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dih_treasury_trial_subsidies_annual) buys you [23.4 million patients/year (90% CI: 9.21 million patients/year-93.7 million patients/year)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dih_patients_fundable_annually) trial slots per year.

Your species currently enrolls [1.9 million patients/year (95% CI: 1.5 million patients/year-2.3 million patients/year)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-current_trial_slots_available) in clinical trials globally. The treaty adds [12.3x (90% CI: 4.92x-50.8x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_multiplier) more capacity on top of that. Remember this number. Everything that follows depends on it.

## The Waiting List

You met the queue in the [untapped therapeutic frontier](../../knowledge/problem/untapped-therapeutic-frontier.llms.md): [6,650 diseases (90% CI: 5,700 diseases-8,232 diseases)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-diseases_without_effective_treatment) with zero approved treatments, and [15](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-new_disease_first_treatments_per_year) getting their first treatment per year. At that rate, you clear the backlog in [443 years (90% CI: 255 years-841 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-status_quo_queue_clearance_years). I will let you sit with that number for a moment. It is longer than your species has had writing.

[![With \$58.6 billion in annual R&D savings, you could run 10,000 trials and address 7,000 rare diseases. Currently you are spending that much to run far fewer trials for common diseases.](../../assets/images/health-dividend/health-dividend-section-what-var-dfda-benefit-rd-only-annual-buys-you-bw-academic.jpg)](../../assets/images/health-dividend/health-dividend-section-what-var-dfda-benefit-rd-only-annual-buys-you-bw-academic.jpg)

With \$58.6 billion in annual R&D savings, you could run 10,000 trials and address 7,000 rare diseases. Currently you are spending that much to run far fewer trials for common diseases.

For context, [443](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-status_quo_queue_clearance_years) years ago, Shakespeare was writing plays, Galileo was building telescopes, and your species already had printing presses, universities, and intercontinental shipping. You just had not gotten around to curing most diseases. At this pace, you still will not for another [443 years (90% CI: 255 years-841 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-status_quo_queue_clearance_years).

Apply the [12.3x (90% CI: 4.92x-50.8x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_multiplier) multiplier. Instead of [15](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-new_disease_first_treatments_per_year) diseases getting their first treatment per year, you get [185 diseases/year (90% CI: 63.8 diseases/year-816 diseases/year)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_first_treatments_per_year). The queue clears in [36 years (90% CI: 8.15 years-106 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_queue_clearance_years) instead of [443 years (90% CI: 255 years-841 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-status_quo_queue_clearance_years). The average untreated disease gets its first treatment [204 years (90% CI: 116 years-390 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_treatment_acceleration_years) earlier. That is the difference between “your grandchildren might see a cure” and “you might see a cure.” Most observers consider this a meaningful distinction. On Earth, it apparently requires a 78-page chapter to justify.

Your species figured out how to split atoms in 6 years during a war, but letting a cancer patient take a pill that passed safety testing requires the gestation period of three consecutive elephants. The [12.3x (90% CI: 4.92x-50.8x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_multiplier) multiplier compresses the elephant parade.

But trial capacity is only half the delay. Once a drug passes safety testing, your [regulatory system](../../knowledge/problem/fda-is-unsafe-and-ineffective.llms.md) sits on it for another [8.2 years (90% CI: 4.84 years-11.5 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-efficacy_lag_years) to confirm it works well enough, while people who could be taking it die instead. Add the capacity acceleration and the efficacy lag together: **[212 years (90% CI: 124 years-398 years)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_years)** of dying, condensed into not dying.

## The Body Count

[150 thousand](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-global_disease_deaths_daily) people die from disease every day. While you were reading the previous section, approximately 300 of them did. They are not coming back to find out how the math turned out.

Not all of those deaths are currently preventable, but 92.6% (95% CI: 50%-98%) are *eventually* avoidable with sufficient biomedical research. “Eventually avoidable” does not mean “currently preventable.” It means: given enough research, these diseases have biological solutions. The only category excluded is accidents (falling off things, being hit by things). Every disease, including aging, is a biological process, and biological processes are, in principle, fixable. This is the theoretical ceiling, not a near-term promise.

Over a [212](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_years)-year timeline shift, the cumulative toll: **[10.7 billion deaths (90% CI: 6.24 billion deaths-20.3 billion deaths)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_lives_saved)**. That is [565 billion DALYs (90% CI: 309 billion DALYs-1.08 trillion DALYs)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_dalys) of healthy life, and [1.93 quadrillion hours (90% CI: 1.04 quadrillion hours-3.75 quadrillion hours)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_suffering_hours) of suffering eliminated. These are cumulative, one-time benefits from permanently accelerating the discovery pipeline, the same methodology used to value smallpox eradication. Nobody objected to the methodology when it was used for smallpox. They will object now because the number is larger, which is a strange reason to object to saving more people.

## The Price Tag on Not Being Dead

Your governments already put a price on human life when deciding whether to approve drugs, build highways, or regulate pollution. The standard rate: [\$150,000 (90% CI: \$100,384-\$198,679)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-standard_economic_qaly_value_usd) per quality-adjusted life year. Your species finds this uncomfortable to discuss but does it constantly. You just prefer to do it in footnotes, where the dying can’t see.

The world loses [2.88 billion DALYs/year (90% CI: 2.63 billion DALYs/year-3.12 billion DALYs/year)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-global_annual_daly_burden)^([3](../references.llms.md#ref-ihme-gbd-2021)). 92.6% (95% CI: 50%-98%) are eventually avoidable with sufficient research. At [\$150,000 (90% CI: \$100,384-\$198,679)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-standard_economic_qaly_value_usd)/QALY, that is [\$400 trillion (90% CI: \$252 trillion-\$544 trillion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-global_disease_economic_burden_annual) per year in welfare losses. Multiply by the [212](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_years)-year timeline shift and you get the total economic value of the health dividend: **[\$7.53 quadrillion (90% CI: \$3.08 quadrillion-\$12.8 quadrillion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_economic_value)**.

“But that is more than global GDP!” Yes. GDP ([\$115 trillion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-global_gdp_2025)) measures market transactions. It does not measure the value of not being dead, not being in pain, and not watching your children die of treatable diseases. The [\$150,000 (90% CI: \$100,384-\$198,679)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-standard_economic_qaly_value_usd)/QALY figure is not something I invented. I just multiplied it by the number of sick people, which is also not my fault.

The only debatable input is whether the timeline shift is really ~[212](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_trial_capacity_plus_efficacy_lag_years) years. See the [full derivation](https://papers.acceleratedmedicine.org/dfda-impact.html/#verification-complete-derivation-chains) for how that number is calculated, and the [Monte Carlo simulations](https://papers.acceleratedmedicine.org/dfda-impact.html/#financial-analysis-summary) for what happens when every input varies.

## The Receipt

Your [decentralized FDA](../../knowledge/solution/dfda.llms.md) costs [\$40 million (90% CI: \$33.5 million-\$47.1 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_annual_opex)/year to operate. For reference, this is roughly what your species spends annually on Halloween costumes for dogs. Less than one fighter jet. Less than what FIFA spends on “hospitality” (your word for bribing officials in a building with chandeliers). A system that could test cures for [7,000](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-rare_diseases_count_global) diseases costs less to run than the outfits you put on animals that do not want to wear them.

The R&D savings alone are [\$40.5 billion (90% CI: \$31.4 billion-\$51.5 billion)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_benefit_rd_only_annual)/year, a **[439 (90% CI: 321-600)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_roi_rd_only):1** return without counting a single human life. Include the lives (which you would think someone would, but your species has a long history of not counting the people who die quietly), and the treaty’s total societal return hits **[7.53 million (90% CI: 2.96 million-15.1 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_roi_trial_capacity_plus_efficacy_lag):1**.

The cost per year of healthy life saved: **[\$9.62 (90% CI: \$2.15-\$32)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_direct_funding_cost_per_daly)**. Anti-malaria bed nets, the gold standard of cost-effective interventions, cost [\$184 (90% CI: \$113-\$252)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-bed_nets_cost_per_daly) per DALY. This system operates at [9.2kx (90% CI: 3.5kx-18.9kx)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_vs_bed_nets_multiplier) the cost-effectiveness, at vastly greater scale. This costs less per life-year than mosquito nets and nobody has heard of it. Your species has spent more money marketing energy drinks.

The total campaign investment: [\$1 billion](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_campaign_total_cost). Even the worst case (everything goes wrong, adoption is terrible, the servers catch fire) still returns an [estimated 66:1](https://papers.acceleratedmedicine.org/dfda-impact.html/#simplified-roi-scenario). Your worst medical outcome is better than your best military one.

Every day without this system costs **[\$111 million (90% CI: \$86 million-\$141 million)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-dfda_rd_savings_daily)** in wasted trial spending alone. The regulatory lag is not a safety feature. It is a waiting room where people die. You just gave it a nicer name.

For you personally: if diseases get cured even a few years earlier, the average human gains roughly 50,000 extra hours of life and [\$518,879 (90% CI: \$221,703-\$860,930)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_trajectory_lifetime_income_gain_per_capita) in additional lifetime income (the treaty path multiplies cumulative earnings by [1.57x (90% CI: 1.24x-1.92x)](../../knowledge/appendix/parameters-and-calculations.llms.md#sec-treaty_trajectory_lifetime_income_multiplier)). You spent 17 minutes reading this chapter. That is a 176,000x return on your time and a per-minute income gain that makes your day job look decorative. Your best investment ever was reading. I realize the irony, given that most of you stopped reading 12 paragraphs ago.

See [impact.warondisease.org](https://impact.warondisease.org) for derivations, Monte Carlo simulations, and the comparative cost-effectiveness table.

1\.

Sinn, M. P. *The Continuous Evidence Generation Protocol: Two-Stage Validation (RWE → Pragmatic Trials)*. <https://papers.acceleratedmedicine.org/dfda-protocol.html> (2025) doi:[10.5281/zenodo.18203375](https://doi.org/10.5281/zenodo.18203375)

*We present the Predictor Impact Score (PIS), a novel composite metric operationalizing Bradford Hill causality criteria for automated signal detection from aggregated N-of-1 observational studies. Combined with pragmatic trial confirmation (based on evidence from 108+ embedded trials), this two-stage framework would generate validated outcome labels at 44.1x lower cost than traditional Phase III trials. This enables continuous, population-scale pharmacovigilance and precision dosing recommendations.*

2\.

Sinn, M. P. *Ubiquitous Pragmatic Trial Impact Analysis*. <https://papers.acceleratedmedicine.org/dfda-impact.html> (2025) doi:[10.5281/zenodo.18243914](https://doi.org/10.5281/zenodo.18243914)

*Only 15 diseases/year get their first treatment each year. With 6,650 diseases lacking effective treatments, the backlog would take 443 years to clear. Integrating pragmatic trials into standard healthcare increases trial capacity 12.3x, cutting that timeline from 443 years to 36 years. The average untreated disease gets a treatment 212 years earlier, saving 10.7 billion deaths at \$9.62 per year of healthy life saved.*

3\.

Institute for Health Metrics and Evaluation (IHME). IHME global burden of disease 2021 (2.88B DALYs, 1.13B YLD). *Institute for Health Metrics and Evaluation (IHME)* <https://vizhub.healthdata.org/gbd-results/> (2024)

*In 2021, global DALYs totaled approximately 2.88 billion, comprising 1.75 billion Years of Life Lost (YLL) and 1.13 billion Years Lived with Disability (YLD). This represents a 13% increase from 2019 (2.55B DALYs), largely attributable to COVID-19 deaths and aging populations. YLD accounts for approximately 39% of total DALYs, reflecting the substantial burden of non-fatal chronic conditions. Additional sources: https://vizhub.healthdata.org/gbd-results/ \| https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00757-8/fulltext \| https://www.healthdata.org/research-analysis/about-gbd*

.

4\.

GAO. 95% of diseases have 0 FDA-approved treatments. *GAO* <https://www.gao.gov/products/gao-25-106774> (2025)

*95% of diseases have no treatment Additional sources: https://www.gao.gov/products/gao-25-106774 \| https://globalgenes.org/rare-disease-facts/*

.

5\.

Biotechnology Innovation Organization (BIO). BIO clinical development success rates 2011-2020. *Biotechnology Innovation Organization (BIO)* <https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf> (2021)

*Phase I duration: 2.3 years average Total time to market (Phase I-III + approval): 10.5 years average Phase transition success rates: Phase I→II: 63.2%, Phase II→III: 30.7%, Phase III→Approval: 58.1% Overall probability of approval from Phase I: 12% Note: Largest publicly available study of clinical trial success rates. Efficacy lag = 10.5 - 2.3 = 8.2 years post-safety verification. Additional sources: https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf*

.

6\.

Calculated from Orphanet Journal of Rare Diseases (2024). Diseases getting first effective treatment each year. *Calculated from Orphanet Journal of Rare Diseases (2024)* <https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03398-1> (2024)

*Under the current system, approximately 10-15 diseases per year receive their FIRST effective treatment. Calculation: 5% of 7,000 rare diseases ( 350) have FDA-approved treatment, accumulated over 40 years of the Orphan Drug Act =  9 rare diseases/year. Adding  5-10 non-rare diseases that get first treatments yields  10-20 total. FDA approves  50 drugs/year, but many are for diseases that already have treatments (me-too drugs, second-line therapies). Only  15 represent truly FIRST treatments for previously untreatable conditions.*

7\.

IQVIA Report. Global trial capacity. *IQVIA Report: Clinical Trial Subjects Number Drops Due to Decline in COVID-19 Enrollment* <https://gmdpacademy.org/news/iqvia-report-clinical-trial-subjects-number-drops-due-to-decline-in-covid-19-enrollment/>

*1.9M participants annually (2022, post-COVID normalization from 4M peak in 2021) Additional sources: https://gmdpacademy.org/news/iqvia-report-clinical-trial-subjects-number-drops-due-to-decline-in-covid-19-enrollment/*

.

8\.

Sinn, M. P. *The Political Dysfunction Tax*. <https://manual.warondisease.org/knowledge/appendix/political-dysfunction-tax.html> (2025) doi:[10.5281/zenodo.18603840](https://doi.org/10.5281/zenodo.18603840)

*Quantifying the gap between current global governance and theoretical maximum welfare, estimating a 31-53% efficiency score and \$101 trillion in annual opportunity costs.*

9\.

NIH Common Fund. NIH pragmatic trials: Minimal funding despite 30x cost advantage. *NIH Common Fund: HCS Research Collaboratory* <https://commonfund.nih.gov/hcscollaboratory> (2025)

*The NIH Pragmatic Trials Collaboratory funds trials at \$500K for planning phase, \$1M/year for implementation-a tiny fraction of NIH’s budget. The ADAPTABLE trial cost \$14 million for 15,076 patients (= \$929/patient) versus \$420 million for a similar traditional RCT (30x cheaper), yet pragmatic trials remain severely underfunded. PCORnet infrastructure enables real-world trials embedded in healthcare systems, but receives minimal support compared to basic research funding. Additional sources: https://commonfund.nih.gov/hcscollaboratory \| https://pcornet.org/wp-content/uploads/2025/08/ADAPTABLE_Lay_Summary_21JUL2025.pdf \| https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604499/*

.

10\.

ICER. Value per QALY (standard economic value). *ICER* <https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf> (2024)

*Standard economic value per QALY: \$100,000–\$150,000. This is the US and global standard willingness-to-pay threshold for interventions that add costs. Dominant interventions (those that save money while improving health) are favorable regardless of this threshold. Additional sources: https://icer.org/wp-content/uploads/2024/02/Reference-Case-4.3.25.pdf*

.

11\.

FDA Study via NCBI. Trial costs, FDA study. *FDA Study via NCBI* <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/>

*Overall, the 138 clinical trials had an estimated median (IQR) cost of \$19.0 million (\$12.2 million-\$33.1 million)... The clinical trials cost a median (IQR) of \$41,117 (\$31,802-\$82,362) per patient. Additional sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248200/*

.

12\.

World Health Organization. WHO global health estimates 2024. *World Health Organization* <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates> (2024)

*Comprehensive mortality and morbidity data by cause, age, sex, country, and year Global mortality:  55-60 million deaths annually Lives saved by modern medicine (vaccines, cardiovascular drugs, oncology):  12M annually (conservative aggregate) Leading causes of death: Cardiovascular disease (17.9M), Cancer (10.3M), Respiratory disease (4.0M) Note: Baseline data for regulatory mortality analysis. Conservative estimate of pharmaceutical impact based on WHO immunization data (4.5M/year from vaccines) + cardiovascular interventions (3.3M/year) + oncology (1.5M/year) + other therapies. Additional sources: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates*

.